

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO AN EXCLUSIVE STRATEGIC COLLABORATION WITH GSK

The board of directors (the “**Board**”) of the Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announced that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), a subsidiary of the Company, entered into an exclusive strategic collaboration with GlaxoSmithKline (“**GSK**”) to accelerate bepirovirsen in mainland China at launch.

Under the agreement, CTTQ will be responsible for importation, distribution, hospital access, and promotional and non-promotional activities for bepirovirsen in mainland China. Revenue generated from product sales in China is expected to be recognised by CTTQ. GSK will remain the marketing authorisation holder and retain responsibility for regulatory, quality, pharmacovigilance and global medical strategy. Under the terms of the agreement, CTTQ will purchase bepirovirsen from GSK under agreed supply terms for an initial term of 5.5 years. The term may be extended thereafter by mutual agreement. Pursuant to the agreement, both parties will also have the opportunity to further explore broader collaboration opportunities relating to the Group’s innovative R&D pipeline assets outside China. The collaboration is expected to support the establishment of a long-term strategic relationship between the two parties and lay a strong foundation for future collaboration on innovative therapies.

This strategic collaboration represents another important recognition of the Group by a leading multinational pharmaceutical company (“**MNC**”), following the strategic partnership entered into with Boehringer Ingelheim in April 2024. The collaboration not only further enriches the Group’s innovative product portfolio and is expected to contribute to future revenue growth, but also demonstrates the Group’s strong commercialisation capabilities, extensive market access platform and robust compliance system. Through continuously deepening strategic partnerships with leading global pharmaceutical companies, the Group further strengthens its position as a preferred partner for MNCs in China.

Bepirovirsen is a first-in-class triple action antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). It was granted Breakthrough Therapy designation in China in August 2021 and accepted for Priority Review in April 2026 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The regulatory submission is supported by positive results from the B-Well 1 and B-Well 2 phase III trials, which demonstrated statistically significant and clinically meaningful functional cure rates.

CTTQ is a market leader in hepatitis B in China with one of the country's most comprehensive liver disease portfolios and a broad commercial footprint covering more than 5,000 medical centres across care settings. CTTQ has played a significant role in advancing the diagnosis and treatment of hepatitis B in China. This strategic collaboration with GSK will improve patient access to bepirovirsen in China, to reach more patients, more quickly. In addition, the partnership is expected to further strengthen and complement CTTQ's existing pipelines.

Hepatitis B is a viral infection that can cause both acute and chronic liver disease. Chronic Hepatitis B (CHB) occurs when the immune system is unable to clear the virus, resulting in long-lasting infection. Many patients often require lifelong antiviral therapy for viral suppression; making functional cure a critical goal in disease management. CHB remains a significant public health challenge in China, affecting an estimated 75 million people and causing approximately 450,000 deaths annually^[1]. 84.4% of patients with liver cancer in China are associated with CHB infection^[2]. Chronic hepatitis B is a national health priority in China. The latest *National Action Plan for the Prevention and Treatment of Viral Hepatitis (2025-2030)* has set out functional cure as a treatment goal for Hepatitis B. Functional cure is associated with a meaningful reduction in the risk of long-term complications, including liver cancer^[3].

The Group is one of the earliest pharmaceutical enterprises in China to establish a presence in the hepatology field and has taken a leading role in building a comprehensive liver diseases product portfolio. A number of liver disease blockbusters, including 天晴甘美® (Tianqing Ganmei) and 潤眾® (Runzhong), have played an important role in advancing hepatitis B diagnosis, treatment and disease awareness in China. The Group is currently focused on key areas including metabolic dysfunction-associated steatohepatitis (“**MASH**”), curative therapies for hepatitis B, liver cirrhosis and acute liver injury. Multiple innovative pipeline candidates have entered clinical development stages, including Lanifibranor (pan-PPAR agonist), which is currently undergoing global Phase III clinical trials; TQ-A3334 (TLR-7 agonist) and TQA3605 (HBV core protein allosteric modulator), both of which are in Phase II clinical trials; and Kylo-0603 (THR- β agonist), which is currently in Phase I clinical trials. Going forward, the Group will continue to deepen its strategic presence in the hepatology field, advance cutting-edge innovative therapies, and strive to address significant unmet medical needs globally.

About Bepirovirsen

Bepirovirsen is a triple action investigational antisense oligonucleotide (ASO), designed to inhibit the replication of viral DNA in the body, suppress the level of hepatitis B surface antigen (HBsAg) in the blood, and stimulate the immune system to increase the chances of a durable and sustained response. Bepirovirsen has been recognised by global regulatory authorities for its innovation and potential to address significant unmet need in hepatitis B, with Priority Review, Fast Track and Breakthrough Designations from the US FDA, Priority Review and Breakthrough Therapy designation in China and SENKU designation in Japan.

About GSK

GSK (LSE/NYSE: GSK) is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at [gsk.com](https://www.gsk.com).

Sources:

- [1] WHO Global Hepatitis Report 2024. Available at <https://www.who.int/publications/i/item/9789240091672> (last accessed March 2026)
- [2] Rungay H et al. Global burden of primary liver cancer in 2020 and predictions to 2040. *J Hepatol.* 2022;77:1598–1606. doi: 10.1016/j.jhep.2022.08.021
- [3] EASL, “Clinical Practice Guidelines on the management of hepatitis B virus infection” in *Journal of Hepatology* Volume 83, Issue 2, August 2025, Pages 502–583. Available at: <https://www.sciencedirect.com/science/article/pii/S0168827825001746> (last accessed March 2026)

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 11 May 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.